Recursion (RXRX) Gains After Acquiring Exscientia and Expanding AI Pharma Partnerships Has the Risk Profile Shifted?

• In recent weeks, Recursion Pharmaceuticals has accelerated its AI-driven drug discovery platform through the acquisition of Exscientia and expanded major partnerships with global pharmaceutical leaders including Sanofi, Roche/Genentech, Bayer, Takeda, and Merck KGaA. These collaborations and the unveiling of the Boltz-2 AI model have brought greater industry validation to Recursion’s approach in oncology and rare diseases.
• Industry recognition at prominent AI conferences and executive engagement has highlighted Recursion’s technological advances, underscoring the importance of AI innovation in biopharmaceutical R&D.
• We will explore how Recursion’s acquisition of Exscientia and enhanced AI capabilities could influence the company’s growth and risk outlook.

Find companies with promising cash flow potential yet trading below their fair value.

Recursion Pharmaceuticals Investment Narrative Recap

To be a shareholder in Recursion Pharmaceuticals, you need conviction in the company’s ability to transform AI-driven drug discovery into commercially viable therapies, particularly in high-need areas like oncology and rare diseases. While recent acquisition and partnership momentum has strengthened Recursion’s competitive position, the most immediate catalyst remains the advancement of its pipeline toward late-stage clinical milestones; however, its heavy reliance on pharma collaborations continues to present the primary risk should any agreement underdeliver or end abruptly.

The acquisition of Exscientia is especially relevant as it directly scales Recursion’s AI capabilities and deepens its pipeline, complementing the company’s push to accelerate internal programs such as CDK7 and RBM39. This move, combined with the launch of Boltz-2 and increased industry attention, is likely to support ongoing and future collaborations, but does not diminish the significance of clinical and partnership execution as near-term catalysts.

In contrast, collaboration risk is something investors should keep in mind, particularly as Recursion’s revenue…

Read the full narrative on Recursion Pharmaceuticals (it’s free!)

Recursion Pharmaceuticals’ narrative projects $220.9 million revenue and $35.5 million earnings by 2028. This requires 50.7% yearly revenue growth and a $684.6 million increase in earnings from -$649.1 million.

Uncover how Recursion Pharmaceuticals’ forecasts yield a $6.47 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members estimate Recursion’s fair value from as low as US$1.92 to US$10 across five distinct views. Some point to the importance of successful pharma partnerships as a core driver of medium-term company performance, encouraging you to explore other viewpoints before making up your mind.

Explore 5 other fair value estimates on Recursion Pharmaceuticals – why the stock might be worth less than half the current price!

Build Your Own Recursion Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

Curious About Other Options?

Markets shift fast. These stocks won’t stay hidden for long. Get the list while it matters:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com